Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trialsAlexa B. Kimball, Elisa Muscianisi, Alice B. Gottlieb et al.|The Lancet|2023Cited by 318
Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patientsPeter Theut Riis, Gregor B. E. Jemec, Ditte Marie Lindhardt Saunte et al.|Archives of Dermatological Research|2020Cited by 42